Healthcare

The Melbourne probiotics group has posted record full-year sales and turned profitable, but a move to onshore manufacturing and an unproven clinical trial will test whether the momentum holds.

CSL Limited (ASX:CSL) is attempting to stabilise earnings after guidance cuts, restructuring charges and a delayed Seqirus demerger. Cost reductions and resilient cash generation provide support, but weaker Behring revenue, vaccine-market uncertainty and major Vifor impairments keep the recovery case unsettled.

Cyclopharm Limited (ASX:CYC) entered the second half of 2026 with record revenue and faster US Technegas sales, but its most closely watched installation milestone has moved beyond the original timeline. The result presents two competing signals: commercial traction is building, while the pace of …

ResMed Inc. (NYSE: RMD; ASX: RMD) has returned to investor conversations after agreeing to sell its MatrixCare out-of-hospital software business, unwinding part of a decade-long diversification push to refocus on its core sleep-apnoea and connected-breathing franchise. For Australian investors, ResMed is a familiar name …

Ramsay Health Care Limited (ASX: RHC), the nation's largest private hospital operator, has spent much of the past two years contending with rising costs, a heavy debt load and a listless share price. In late July 2026 the tone looked marginally brighter. RHC shares …

CSL Limited (ASX: CSL), the Melbourne-headquartered blood-plasma and vaccines group that ranks among Australia's largest listed healthcare companies, has staged a notable share-price recovery after one of the most punishing years in its history. By the close on Tuesday 28 July 2026, CSL shares …

Lumos Diagnostics is a point-of-care diagnostics company whose lead product, FebriDx, is a rapid test used at the point of care to help clinicians tell whether a patient’s acute respiratory infection is more likely bacterial or viral. Using a small finger-prick blood sample, FebriDx …